[1]Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies[J]. Cell, 2019,179:312-339. doi: 10.1016/j.cell.2019.09.001. [2]McAlpine CS, Park J, Griciuc A, et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer′s disease[J]. Nature, 2021, 595:701-706. doi: 10.1038/s41586-021-03734-6. [3]Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367:eaau6977. doi: 10.1126/science.aau6977. [4]Li Q, Fu X, Kou Y, et al. Engineering strategies and optimized delivery of exosomes for theranostic application in nerve tissue[J]. Theranostics, 2023,13:4266-4286. doi: 10.7150/thno.84971. [5]Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation[J]. Immunity, 2019, 50:796-811. doi: 10.1016/j.immuni.2019.03.022. [6]Wang ZB, Ma YH, Sun Y, et al. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer′s disease[J]. J Neuroinflammation, 2022, 19:316.doi: 10.1186/s12974-022-02679-5. [7]Zambrano A, Otth C, Maccioni RB, et al. IL-3 controls tau modifications and protects cortical neurons from neurodegeneration[J]. Curr Alzheimer Res, 2010, 7:615-624. doi: 10.2174/156720510793499011. [8]Li W, Li C, Zhou T, et al. Role of exosomal proteins in cancer diagnosis[J]. Mol Cancer, 2017, 16:145. doi: 10.1186/s12943-017-0706-8. [9]Salunkhe S, Dheeraj, Basak M, et al. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance[J]. J Control Release, 2020, 326:599-614. doi: 10.1016/j.jconrel.2020.07.042. [10]Zhang T, Ma S, Lv J, et al. The emerging role of exosomes in Alzheimer′s disease[J]. Ageing Res Rev, 2021, 68:101321. doi: 10.1016/j.arr.2021.101321. [11]Malm T, Loppi S, Kanninen KM. Exosomes in Alzheimer′s disease[J]. Neurochem Int, 2016, 97:193-199. doi: 10.1016/j.neuint.2016.04.011. [12]刁华琼, 李小黎, 林亮吟,等.外泌体microRNAs与阿尔茨海默病关系的研究进展[J]. 基础医学与临床, 2020, 40: 1542-1545. |